SGLT2 inhibitors for pediatric Duchenne-related cardiomyopathy
Official title: CHERISH (duCHennE caRdiomyopathy mItigation Sglt2 inHibitor)
Funded at Vanderbilt University Medical Center · NIH-11607308 · Data updated 2026-11-12
A pediatric-focused study tests whether a diabetes drug class (SGLT2 inhibitors) can help heart disease linked to Duchenne muscular dystrophy in children and young adults.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University Medical Center NIH-funded |
| Lab location | 1 site (Nashville, United States) |
| Project start | September 4, 2025 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $521,396 |
| NIH project number | 7R61HL180327-02 |
| Project ID | NIH-11607308 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal participants are pediatric and young adult patients with progressive Duchenne-related cardiomyopathy.
✕Less likely to help
Patients without Duchenne muscular dystrophy–related cardiomyopathy or without progressive CM may not directly benefit.
What this research studies
This project looks at how SGLT2 inhibitors may support heart health in kids and young adults with Duchenne-related cardiomyopathy. It focuses on understanding the way the drug works in this population and finds the right dosing for pediatric patients. The study would involve a mechanistic approach in a group with progressive cardiomyopathy to see potential heart-related benefits and safety signals. By clarifying dosing and biological effects, it aims to inform future therapies tailored to pediatric patients with DMD-associated heart disease.
Why it matters
Potential benefit: If successful, the study could guide safer, more effective use of SGLT2 inhibitors to improve survival and heart function in children and young adults with Duchenne-related cardiomyopathy.
How similar studies have gone: Previous adult studies show mortality benefits from SGLT2 inhibitors in cardiomyopathy, but pediatric data are limited and this study could provide new insights.
Where this research is happening
-
Vanderbilt University Medical Center
Nashville, United States Active
Researchers
- Principal investigator: Markham, Larry W. — Vanderbilt University Medical Center
- Study coordinator: Markham, Larry W.
Related research
Other NIH-funded projects on the same topics.
-
Global bromocriptine trial for postpartum cardiomyopathy
A large international study will test whether adding bromocriptine to standard heart failure treatment helps new mothers with peripartum cardiomyopathy.
-
Global Bromocriptine Add-on for Postpartum Heart Failure (GLOBal PPCM)
A large international study will test whether adding the dopamine agonist bromocriptine to standard heart failure care helps postpartum women with a specific heart condition.
-
Global Bromocriptine Trial for Postpartum Heart Failure (GLOBal PPCM)
A large international study will test whether adding bromocriptine to standard heart-failure care helps women with postpartum cardiomyopathy.
-
Bromocriptine as add-on therapy for postpartum cardiomyopathy across multiple sites
A large international study will test whether adding bromocriptine to standard heart failure treatment helps new mothers with postpartum cardiomyopathy.
-
Global bromocriptine trial to help postpartum heart failure patients
A large international trial tests whether adding bromocriptine to standard heart failure treatment improves outcomes for new mothers with a specific pregnancy-related heart condition.
-
Global Bromocriptine Trial to Help Postpartum Heart Failure
A large international study will test whether adding bromocriptine to standard heart failure treatment helps women with postpartum cardiomyopathy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.